Evidence map›Paper›PMID 34630653›Full record

ArticleExperimental and therapeutic medicine2021

Patients affected by squamous cell carcinoma of the head and neck: A population particularly prone to developing severe forms of COVID-19.

Francesco Perri, Anna Crispo, Franco Ionna, Paolo Muto, Francesco Caponigro, Francesco Longo, Concetta Montagnese, Pierluigi Franco, Ettore Pavone, Corrado Aversa and 9 more

Open access · diamondAbstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Francesco PerriHead and Neck Medical and Experimental Oncology Unit, Istituto Nazionale Tumori, IRCCS 'Fondazione G. Pascale', I-80131 Naples, Italy.
Anna CrispoEpidemiology and Biostatistics Unit, Istituto Nazionale Tumori, IRCCS 'Fondazione G. Pascale', I-80131 Naples, Italy.
Franco IonnaOtolaryngology Unit, Istituto Nazionale Tumori, IRCCS 'Fondazione G. Pascale', I-80131 Naples, Italy.
Paolo MutoRadiation Oncology Unit, Istituto Nazionale Tumori, IRCCS 'Fondazione G. Pascale', I-80131 Naples, Italy.
Francesco CaponigroHead and Neck Medical and Experimental Oncology Unit, Istituto Nazionale Tumori, IRCCS 'Fondazione G. Pascale', I-80131 Naples, Italy.
Francesco LongoOtolaryngology Unit, Casa Sollievo della Sofferenza di San Giovanni Rotondo, I-71013 Foggia, Italy.
Concetta MontagneseEpidemiology and Biostatistics Unit, Istituto Nazionale Tumori, IRCCS 'Fondazione G. Pascale', I-80131 Naples, Italy.
Pierluigi FrancoOtolaryngology Unit, Istituto Nazionale Tumori, IRCCS 'Fondazione G. Pascale', I-80131 Naples, Italy.
Ettore PavoneOtolaryngology Unit, Istituto Nazionale Tumori, IRCCS 'Fondazione G. Pascale', I-80131 Naples, Italy.
Corrado AversaOtolaryngology Unit, Istituto Nazionale Tumori, IRCCS 'Fondazione G. Pascale', I-80131 Naples, Italy.
Agostino GuidaOtolaryngology Unit, Istituto Nazionale Tumori, IRCCS 'Fondazione G. Pascale', I-80131 Naples, Italy.
Sabrina BimonteDepartment of Anesthesia and Pain Medicine, Istituto Nazionale Tumori, IRCCS 'Fondazione G. Pascale', I-80131 Naples, Italy.
Alessandro OttaianoInnovative Therapies for Abdominal Metastases, Department of Abdominal Oncology, Istituto Nazionale Tumori, IRCCS 'Fondazione G. Pascale', I-80131 Naples, Italy.
Massimiliano Di MarzoColorectal and Abdominal Surgery Unit, Istituto Nazionale Tumori, IRCCS 'Fondazione G. Pascale', I-80131 Naples, Italy.
Giuseppe PorcielloEpidemiology and Biostatistics Unit, Istituto Nazionale Tumori, IRCCS 'Fondazione G. Pascale', I-80131 Naples, Italy.
Alfonso AmoreDepartment Melanoma, Soft Tissue, Muscle-Skeletal and Head-Neck, Istituto Nazionale Tumori, IRCCS 'Fondazione G. Pascale', I-80131 Naples, Italy.
Egidio CelentanoEpidemiology and Biostatistics Unit, Istituto Nazionale Tumori, IRCCS 'Fondazione G. Pascale', I-80131 Naples, Italy.
Giuseppina Della Vittoria ScarpatiMedical Oncology Unit, San Rocco Hospital, Sessa Aurunca, I-81037 Caserta, Italy.
Marco CascellaDepartment of Anesthesia and Pain Medicine, Istituto Nazionale Tumori, IRCCS 'Fondazione G. Pascale', I-80131 Naples, Italy.
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITCasa Sollievo della Sofferenza · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the recent Coronavirus Disease 2019 (COVID-19) pandemic, which has spread all over the world over the past year. Comorbidities appear to affect the prognosis of patients with such diseases, but the impact of cancer on the course of SARS-CoV2 has remained largely elusive. The aim of the present study is to analyze the outcome of patients affected by squamous cell carcinoma of the head and neck (SCCHN) and a number of their comorbidities, if infected with SARS-CoV2. The clinical data of 100 patients affected by SCCHN, who were undergoing treatment or who had finished their oncologic treatment in the past 6 months, were retrospectively collected and analysed. For each patient, the Charlson Comorbidity Index (CCI) was calculated to provide a score assessing the real weight of comorbidities on the patient's outcome at the time of diagnosis. It was discovered that these patients, besides the SCCHN, frequently presented at diagnosis with several other comorbidities, including hypertension, type 2 diabetes, cardiac arrhytmia, chronic obstructive pulmonary disease and various forms of vasculopathy (and thus a poor CCI). This feature suggest that, given the high frequency of various comorbidities in patients with SCCHN, additional SARS-CoV2 infection could have particularly devastating consequences.

Indexed as

cancerCharlson comorbidity indexCOVID-19SARS-COV-2squamous cell carcinoma of the head and neck

Identifiers

PMID34630653
PMCPMC8461515
OpenAlexW3201579645

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.